Table 2. OR of factors related to... | American Society of Hematology

Table 2.

OR of factors related to primary outcomes

	OR	95% CI	P
Female vs male	1.46	0.35-6.16	.60
Age, >42 y	0.38	0.09-1.59	.19
BCS vs PVT	0.48	0.12-1.86	.29
PMF vs others	5.58	0.8-38.6	.08
JAK2 vs CALR mutation	0.54	0.05-5.4	.61
JAK2 V617F ≥50%	14.7	3.2-67.9	<.001
Additional mutation	5.7	1.11-28.6	.03
DNA methylation	0.93	0.22-4	.92
Chromatin/spliceosome	9	2.1-39	.003
TP53 mutation	4.3	0.35-53	.25
Cytoreductive therapy	0.24	0.04-1.54	.13

	OR	95% CI	P
Female vs male	1.46	0.35-6.16	.60
Age, >42 y	0.38	0.09-1.59	.19
BCS vs PVT	0.48	0.12-1.86	.29
PMF vs others	5.58	0.8-38.6	.08
JAK2 vs CALR mutation	0.54	0.05-5.4	.61
JAK2 V617F ≥50%	14.7	3.2-67.9	<.001
Additional mutation	5.7	1.11-28.6	.03
DNA methylation	0.93	0.22-4	.92
Chromatin/spliceosome	9	2.1-39	.003
TP53 mutation	4.3	0.35-53	.25
Cytoreductive therapy	0.24	0.04-1.54	.13